PALB2 and breast carcinoma: Furthermore, the reversion mutations were not only detected in BRCA1/2, but also in other HRR pathway genes including RAD51C, RAD51D, and PALB2 in ovarian, prostate, and breast carcinomas as a mechanism of acquired resistance to platinum-based chemotherapies and PARPIs.